The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
Allison Agwu; Jane C Lindsey; Kimberly Ferguson; Haili Zhang; Stephen Spector; Bret J Rudy; Stuart C Ray; Steven D Douglas; Patricia M Flynn; Deborah Persaud; et al. (Profiled Authors: Stuart Ray; Allison Agwu; Deborah Persaud)
Department of Pediatrics, Division of Infectious Diseases, Johns Hopkins Medical Institution, Baltimore, Maryland, USA.
AIDS patient care and STDs 2008;22(7):545-52.
Treatment failure and drug resistance create obstacles to long-term management of HIV-1 infection. Nearly 60% of infected persons fail their first highly active antiretroviral therapy (HAART) regimen, partially because of nonadherence, requiring a switch to a second regimen to prevent drug resistance. Among HIV-infected youth, a group with rising infection rates, treatment switch is often delayed; virologic and immunologic consequences of this delay are unknown. We conducted a retrospective, longitudinal study of drug resistance outcomes of initial HAART in U.S. youth enrolled between 1999-2001 in a multicenter, observational study and experiencing delayed switch in their first nonsuppressive treatment regimen for up to 3 years. HIV-1 genotyping was performed on plasma samples collected longitudinally, and changes in drug resistance mutations, CD4+ T cell numbers and viral replication capacity were assessed. Forty-four percent (n = 18) of youth in the parent study experiencing virologic nonsuppression were maintained on their initial HAART regimen for a median of 144 weeks. Drug resistance was detected in 61% (11/18) of subjects during the study. Subjects on non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens developed more (8/10) drug resistance mutations than those on protease-inhibitor (PI) regimens (2/7) (p = 0.058). Subjects developing NNRTI-resistance (NNRTI-R), showed a trend toward lower CD4+ T cell gains (median: -6 cells/mm(3) per year) than those without detectable NNRTI-R (median: +149 cells/mm(3) per year) (p = 0.16). HIV-1-infected youth maintained on initial nonsuppressive NNRTI-based HAART regimens are more likely to develop drug-resistant viremia than with PI-based HAART. This finding may have implications for initial treatment regimens and transmission risk in HIV-infected youth, a group with rising infection rates.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
William I Towler; Linda Barlow-Mosha; Jessica D Church; Danstan Bagenda; Patrick Ajuna; Micheal Mubiru; Philippa Musoke; Susan H EshlemanAIDS research and human retroviruses 2010;26(5):563-8.
Daniel Podzamczer; Martin S King; Cheri E Klein; Charles Flexner; Christine Katlama; Diane V Havlir; Scott L Letendre; Joseph J Eron; Scott C Brun; Barry BernsteinHIV clinical trials 2007;8(4):193-204.
Amita Gupta; Dattaray G Saple; Girish Nadkarni; Bijal Shah; Satish Vaidya; Nitin Hingankar; Devidas Chaturbhuj; Praveen Deshmukh; Louise Walshe; Sarah E Hudelson; et al.AIDS research and human retroviruses 2010;26(1):25-31.
Appears in this Publication
Author of this Publication